Illustrations on the mode of action of a BTK inhibitor in CLL (chronic lymphocytic leukemia) on the B cells in the lymph nodes.
In chronic lymphocytic leukemia, the number of B cells is abnormally elevated.The lymph nodes are swollen due to the insertion of B cells. The active substance "Ibrutinib" blocks the interaction of BTK (Brutone Tyrosine Kinase) and transcription factor NFkB in the B cells, which enables cell death and thereby reduces their number. As more and more B-cells and also BTK are produced, a continuous intake of the drug is necessary to reduce the number of B-cells.
Content: 5 illustrations
Utilization: printed information folder for sales force
Specifications: Print, DIN A5 / 300dpi
Client: Sir Prise & Lady Buy / Janssen Swiss
The rights of use of the illustrations shown are with the respective clients. The images are protected with a watermark.
The drug binds to the BTK and prevents interaction with the transcription factor NFkB
Because BTK is still being re-produced by the B cell, the drug must be taken continuously
Rough sketch of the images for usage in pre-production